Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.DSM Biologics, a business unit of DSM Pharmaceutical Products, has reported results of its XD process technology, a platform approach used to produce an Fc-fusion protein in a CHO cell line.
Subscribe to our email newsletter
The results showed a record viable cell density of 242 million cells per ml at day 15, and a record titer achievement for a Fc-fusion protein of 11.5g per liter (corrected for biomass) compared to a 1.2g per L liter titer in standard fed-batch processing.
DSM Biologics Global R&D vice president Rolf Douwenga said biopharmaceuticals can be processed at greatly reduced costs if the XD process technology combined with DSM’s proprietary Rhobust capture and clarification technology.
The Rhobust technology, an expanded bed chromatography (EBA), using cross linked agarose beads with Tungsten Carbide to increase the particle density, is applied as direct capture step for mammalian and microbial harvest to increase yields, reduce the number of unit operations and reduce process cost.
DSM Biologics has earlier reported scalability of the XD process, and demonstrated consistent results in scaling the process from 2L to 50L in its cGMP manufacturing facility in Groningen, Holland.